Deferoxamine in the management of COVID-19 adult patients admitted to ICU: a prospective observational cohort study.

Abdulaziz M AlmutarySaqer AlthunayyanAmal S BagalbAhmed F MadyLatifa AlenaziShahzad A MumtazZahrah Al-HammadBasheer AbdulrahmanMohammed A Al-OdatHuda MhawishWaleed Th AletrebyMaymouna AltartouriZiad A Memish

Published in: Annals of medicine and surgery (2012) (2023)

Deferoxamine may have mortality and clinical improvement benefits in COVID-19 adults admitted to ICU. Further powered and controlled studies are required.

Keyphrases

coronavirus disease
sars cov
intensive care unit
mechanical ventilation
cardiovascular events
respiratory syndrome coronavirus
coronary artery disease
acute respiratory distress syndrome
case control
young adults